bluebird bio, Inc. (BLUE)
After hours:
| Previous close | 3.0600 |
| Open | 3.0300 |
| Bid | 0.0000 x 3200 |
| Ask | 0.0000 x 4000 |
| Day's range | 2.9600 - 3.0450 |
| 52-week range | 2.7800 - 8.5800 |
| Volume | |
| Avg. volume | 4,167,141 |
| Market cap | 322.998M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
bluebird bio Announces September Investor Events
SOMERVILLE, Mass., September 05, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:
- Business Wire
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
SOMERVILLE, Mass., August 16, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel). Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) with a proposed indication for patients ages 12 and older who have a history of vaso-occlusive events (VOEs). The Agency previously
- Business Wire
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass., August 08, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the second quarter ended June 30, 2023, including recent commercial and operational progress, and regulatory updates.
